St. Jude (STJ) Lower; New Preliminary Data Showing Riata Did Not Prevent Durata Insulation Abrasions
Get Alerts STJ Hot Sheet
Join SI Premium – FREE
St. Jude Medical (NYSE: STJ) is heading lower Tuesday morning following publication of a new research report for its Durata ICD.
Specifically, the study was conducted by Dr. Robert Houser and focused on Durata lead failures. Houser cautions that data is preliminary and hypothesis generating and additional studies are needed.
The conclusion from the study is that Durata leads failed due to insulation abrasions. Riata ST Optim did not prevent the abrasions, which Houser and his team said developed under 4 years after implant.
For more on the publication, click here.
The report comes following headlines last week that the FDA was going to order a review of Riata Defibrillator leads. Shares of St. Jude are down about 0.2 percent in early trading.
Specifically, the study was conducted by Dr. Robert Houser and focused on Durata lead failures. Houser cautions that data is preliminary and hypothesis generating and additional studies are needed.
The conclusion from the study is that Durata leads failed due to insulation abrasions. Riata ST Optim did not prevent the abrasions, which Houser and his team said developed under 4 years after implant.
For more on the publication, click here.
The report comes following headlines last week that the FDA was going to order a review of Riata Defibrillator leads. Shares of St. Jude are down about 0.2 percent in early trading.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Creative Medical completes enrollment in ADAPT back pain trial
- Zipalertinib trial data to be presented at IASLC lung cancer conference
- FDA approves Regeneron's Pasatru for rare bone disorder FOP
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share